Active Ingredient History
Tinzaparin is an antithrombotic drug in the heparin group. It is a low molecular weight heparin (LMWH) marketed as Innohep worldwide. It has been approved by the U.S. Food and Drug Administration (FDA) for once daily treatment and prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE). Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Chest Syndrome (Phase 3)
Acute Kidney Injury (Phase 4)
Adenocarcinoma (Phase 3)
Anemia (Phase 3)
Anemia, Sickle Cell (Phase 3)
Anticoagulants (Phase 4)
Carcinoma, Non-Small-Cell Lung (Phase 3)
COVID-19 (Phase 3)
Diabetes Mellitus (Phase 4)
Fetal Growth Retardation (Phase 4)
General Surgery (Phase 4)
Hemorrhage (Phase 4)
Heparin, Low-Molecular-Weight (Phase 3)
Ischemic Stroke (Phase 2)
Kidney Failure, Chronic (Phase 4)
Kidney Neoplasms (Phase 1/Phase 2)
Liver Neoplasms (Phase 4)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 2)
Multiple Myeloma (Phase 2)
Neoplasms (Phase 2)
Postthrombotic Syndrome (Phase 4)
Pulmonary Embolism (Phase 4)
Renal Dialysis (Phase 4)
Renal Replacement Therapy (Phase 4)
Thromboembolism (Phase 4)
Thrombosis (Phase 4)
Venous Thromboembolism (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
